Biomarin Pharmaceutical Inc (BMRN)
66.60
+0.71
(+1.08%)
USD |
NASDAQ |
Nov 01, 16:00
66.60
0.00 (0.00%)
After-Hours: 20:00
Biomarin Pharmaceutical Revenue (Quarterly): 745.74M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 745.74M |
| June 30, 2024 | 712.03M |
| March 31, 2024 | 648.83M |
| December 31, 2023 | 646.21M |
| September 30, 2023 | 581.33M |
| June 30, 2023 | 595.28M |
| March 31, 2023 | 596.42M |
| December 31, 2022 | 537.54M |
| September 30, 2022 | 505.34M |
| June 30, 2022 | 533.80M |
| March 31, 2022 | 519.36M |
| December 31, 2021 | 449.81M |
| September 30, 2021 | 408.74M |
| June 30, 2021 | 501.69M |
| March 31, 2021 | 486.03M |
| December 31, 2020 | 452.12M |
| September 30, 2020 | 476.78M |
| June 30, 2020 | 429.48M |
| March 31, 2020 | 502.04M |
| December 31, 2019 | 454.44M |
| September 30, 2019 | 461.10M |
| June 30, 2019 | 387.76M |
| March 31, 2019 | 400.74M |
| December 31, 2018 | 353.26M |
| September 30, 2018 | 391.71M |
| Date | Value |
|---|---|
| June 30, 2018 | 372.84M |
| March 31, 2018 | 373.45M |
| December 31, 2017 | 358.30M |
| September 30, 2017 | 334.15M |
| June 30, 2017 | 317.45M |
| March 31, 2017 | 303.74M |
| December 31, 2016 | 300.09M |
| September 30, 2016 | 279.90M |
| June 30, 2016 | 300.13M |
| March 31, 2016 | 236.74M |
| December 31, 2015 | 227.94M |
| September 30, 2015 | 208.90M |
| June 30, 2015 | 250.14M |
| March 31, 2015 | 202.92M |
| December 31, 2014 | 230.07M |
| September 30, 2014 | 176.55M |
| June 30, 2014 | 191.79M |
| March 31, 2014 | 151.55M |
| December 31, 2013 | 146.87M |
| September 30, 2013 | 136.87M |
| June 30, 2013 | 136.81M |
| March 31, 2013 | 127.93M |
| December 31, 2012 | 131.94M |
| September 30, 2012 | 128.12M |
| June 30, 2012 | 124.02M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
408.74M
Minimum
Sep 2021
745.74M
Maximum
Sep 2024
539.15M
Average
512.35M
Median
Revenue (Quarterly) Benchmarks
| Merck & Co Inc | 16.66B |
| Bristol-Myers Squibb Co | 11.89B |
| Alnylam Pharmaceuticals Inc | 500.92M |
| Bioventus Inc | 151.22M |
| Moderna Inc | 221.00M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 106.08M |
| Total Expenses (Quarterly) | 631.87M |
| EPS Diluted (Quarterly) | 0.55 |
| Enterprise Value | 12.36B |
| Gross Profit Margin (Quarterly) | 74.73% |
| Profit Margin (Quarterly) | 14.22% |
| Earnings Yield | 2.51% |
| Operating Earnings Yield | 2.39% |
| Normalized Earnings Yield | 2.444 |